View in EDS

USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-I.

Saved in:
Bibliographic Details
Title: USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-I.
Authors: Liu K; Department of Pathology, Robert H. Lurie Comprehensive Cancer Center and Center for Human Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Iyer R; Department of Pathology, Robert H. Lurie Comprehensive Cancer Center and Center for Human Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Li Y; Department of Oncology, 920th Hospital of Joint Logistics Support Force, Kunming, China., Zhu J; Department of Oncology, 920th Hospital of Joint Logistics Support Force, Kunming, China., Cai Z; Department of Pathology, Robert H. Lurie Comprehensive Cancer Center and Center for Human Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Wei J; Center of Metabolic Disease Research, Department of Cardiovascular Sciences, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA., Cheng Y; Department of Pathology, Robert H. Lurie Comprehensive Cancer Center and Center for Human Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Tang AY; Department of Pathology, Robert H. Lurie Comprehensive Cancer Center and Center for Human Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Wang H; Department of Pathology, Robert H. Lurie Comprehensive Cancer Center and Center for Human Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Gao Q; Department of Pathology, Robert H. Lurie Comprehensive Cancer Center and Center for Human Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Mani NL; Department of Pathology, Robert H. Lurie Comprehensive Cancer Center and Center for Human Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Marx N; Department of Pathology, Robert H. Lurie Comprehensive Cancer Center and Center for Human Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Gao B; Department of Pathology, Robert H. Lurie Comprehensive Cancer Center and Center for Human Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Watterson DM; Department of Pharmacology., Khan SA; Division of Breast Surgery, Robert H. Lurie Comprehensive Cancer Center., Gradishar WJ; Division of Hematology/Oncology, Department of Medicine, and., Liu H; Department of Pharmacology.; Department of Medicine, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Fang D; Department of Pathology, Robert H. Lurie Comprehensive Cancer Center and Center for Human Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Source: The Journal of clinical investigation [J Clin Invest] 2025 Nov 18; Vol. 136 (1). Date of Electronic Publication: 2025 Nov 18 (Print Publication: 2026).
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: eCollection Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1558-8238
DOI:10.1172/JCI193162